Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW-LTE long-term extension study of RAY121 in immune-mediated diseases
NL-OMON59784Phase 1Not yet recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RAY121 in Behçet's disease (BD), immune thrombocytopenia (ITP), antiphospholipid syndrome (APS) and 3 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary endpoint(s). Planned start Mar 2025; status: not yet recruiting.
02
Drugs
RAY121
03
Conditions
Behçet's disease (BD)immune thrombocytopenia (ITP)antiphospholipid syndrome (APS)dermatomyositis (DM)Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NL-OMON59784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59784.